The Evolving Role of Next-Generation Sequencing in NSCLC Management

Biomarker testing has added another layer to surgical planning in early-stage NSCLC, necessitating tighter multidisciplinary coordination.

Jessica Donington, MD, MSCR, discusses how the availability of targeted therapy has affected surgical decision-making in early-stage lung cancer.

Pathologists play a key role in lung cancer care, from biomarker testing to tissue triage.

Jasleen Pannu, MBBS, explains how interventional pulmonologists guide timely molecular testing and treatment through lung cancer diagnosis, staging, and tissue acquisition.

Jasleen Pannu, MBBS, discusses the importance of proactive biomarker ordering and close multidisciplinary collaboration in optimal lung cancer care.

Cynthia A. Schandl, MD, PhD, discusses the role of the pathologist in expediting biomarker-driven treatment decisions in lung cancer care.

Adam Fox, MD, and Cynthia A. Schandl, MD, PhD, examined the expanding role of biomarker testing and genomic profiling in NSCLC across disease stages.

Mark A. Socinski, MD, and Martin F. Dietrich, MD, PhD, discuss molecular testing methodologies for NSCLC.

David P. Carbone, MD, PhD, and Niels Reinmuth, MD, PhD, discussed the landscapes of biomarker testing and screening in NSCLC.

Adam Fox, MD, discusses the process and timing of ordering NGS testing for patients with NSCLC.

Adam Fox, MD, discusses the need for molecular profiling in non–small cell lung cancer and how these results factor into multidisciplinary planning.